Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studiesDRAGOVICH, P. S; WEBBER, S. E; TIKHE, J et al.Journal of medicinal chemistry (Print). 1998, Vol 41, Num 15, pp 2819-2834, issn 0022-2623Article

Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitorsDRAGOVICH, P. S; RU ZHOU; MEADOR, J. W et al.Bioorganic & medicinal chemistry letters (Print). 2000, Vol 10, Num 1, pp 45-48, issn 0960-894XArticle

HeLa cell RNA polymerase III transcription factors: functional characterization of a fraction identified by its activity in a second template rescue assayFUHRMAN, S. A; ENGELKE, D. R; GEIDUSCHEK, E. P et al.The Journal of biological chemistry (Print). 1984, Vol 259, Num 3, pp 1934-1943, issn 0021-9258Article

Mechanism of resistance to complement-mediated killingFUHRMAN, S. A; JOINER, K. A.The Journal of immunology (1950). 1989, Vol 142, Num 3, pp 940-947, issn 0022-1767Article

Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C proteaseWEBBER, S. E; TIKHE, J; BROWN, E. L et al.Journal of medicinal chemistry (Print). 1996, Vol 39, Num 26, pp 5072-5082, issn 0022-2623Article

Toxoplasma gondii : fusion competence of parasitophorous vacuoles in Fc receptor : transfected fibroblastsJOINER, K. A; FUHRMAN, S. A; MIETTINEN, H. M et al.Science (Washington, D.C.). 1990, Vol 249, Num 4969, pp 641-646, issn 0036-8075, 6 p.Article

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P₁ lactam moieties as L-glutamine replacementsDRAGOVICH, P. S; PRINS, T. J; BURKE, B. J et al.Journal of medicinal chemistry (Print). 1999, Vol 42, Num 7, pp 1213-1224, issn 0022-2623Article

In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C proteasePATICK, A. K; BINFORD, S. L; FUHRMAN, S. A et al.Antimicrobial agents and chemotherapy. 1999, Vol 43, Num 10, pp 2444-2450, issn 0066-4804Article

Delivering clinical laboratory services to intensive care unitsSTEFFES, M. W; GILLEN, J. L; FUHRMAN, S. A et al.Clinical chemistry (Baltimore, Md.). 1996, Vol 42, Num 3, pp 387-391, issn 0009-9147Article

Mass spectrometric detection of the noncovalent GDP-bound conformational state of the human H-ras proteinGANGULY, A. K; PRAMANIK, B. N; TSARBOPOULOS, A et al.Journal of the American Chemical Society. 1992, Vol 114, Num 16, pp 6559-6560, issn 0002-7863Article

Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acidsDRAGOVICH, P. S; WEBBER, S. E; BROWN, E. L et al.Bioorganic & medicinal chemistry letters (Print). 1999, Vol 9, Num 15, pp 2189-2194, issn 0960-894XArticle

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimeticsDRAGOVICH, P. S; PRINS, T. J; ZHOU, R et al.Journal of medicinal chemistry (Print). 1999, Vol 42, Num 7, pp 1203-1212, issn 0022-2623Article

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studiesDRAGOVICH, P. S; WEBBER, S. E; LITTLEFIELD, E. S et al.Journal of medicinal chemistry (Print). 1998, Vol 41, Num 15, pp 2806-2818, issn 0022-2623Article

Tripeptide aldehyde inhibitors of human rhinovirus 3C protease : Design, synthesis, biological evaluation, and cocrystal structure solution of P₁ glutamine isosteric replacementsWEBBER, S. E; OKANO, K; MEADOR, J. W et al.Journal of medicinal chemistry (Print). 1998, Vol 41, Num 15, pp 2786-2805, issn 0022-2623Article

Marked hyperbilirubinemia in infectious mononucleosis: analysis of laboratory data in seven patientsFUHRMAN, S. A; GILL, R; HORWITZ, C. A et al.Archives of internal medicine (1960). 1987, Vol 147, Num 5, pp 850-853, issn 0003-9926Article